Arrowhead Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2830 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Jan 17th, 2025 9:30 pm
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial - Dec 24th, 2024 1:20 pm
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Dec 23rd, 2024 12:30 pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 19th, 2024 9:59 pm
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases - Dec 11th, 2024 12:30 pm
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) have lost 66%, as stock drops 9.3% this past week - Dec 7th, 2024 2:31 pm
Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment - Dec 4th, 2024 12:40 pm
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Dec 3rd, 2024 12:30 pm
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing… - Dec 3rd, 2024 11:24 am
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Dec 2nd, 2024 12:30 pm
Arrowhead price target lowered to $24 from $27 at Bernstein - Nov 30th, 2024 11:00 am
Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance - Nov 29th, 2024 6:00 am
Sarepta price target lowered to $202 from $205 at Needham - Nov 28th, 2024 1:15 pm
Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call - Nov 27th, 2024 5:40 pm
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies - Nov 27th, 2024 4:31 pm
Arrowhead Stock Rockets 16% After Major Licensing Deal - Nov 27th, 2024 4:07 pm
Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments - Nov 27th, 2024 12:21 pm
Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board - Nov 27th, 2024 12:20 pm
Arrowhead and Sarepta link for rare genetic disease treatments - Nov 27th, 2024 9:33 am
Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... - Nov 27th, 2024 7:04 am